Signe has unique applications of plant based technology to bring about the end of breast cancer
Signe's other unique protein-based cancer therapies are ideally suited to transgenic plant production
Proof of concept is in place already based on known plants and known proteins
Signe has selected (a) plant species for its platform that will avoid USDA/FDA issues related to transgenic plant products that are used as human food sources - this is a critical issue
Plant derived proteins will provide the large quantities needed to serve worldwide markets
The plant proteins to be produced by Signe have very large and diverse markets
Signe's proteins will be selected for market diversity to reduce risk and maximize profits
Signe is ideally situated to initiate plant based technology because the first major capital expenditures can be directed to this goal from the onset rather using new funds to redirect away from other bioreactor technology